← Human Trials & Peer-Reviewed Studies
Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial
Plain-language guide to PMID 21232119 (2011): placebo-controlled randomized controlled trial study of Cyanocobalamin (Vitamin B12) in 50 patients.
Key Facts
- PMID
- 21232119
- Journal
- BMC family practice
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Favrat B et al. (8 authors)
- DOI
- 10.1186/1471-2296-12-2
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cyanocobalamin (Vitamin B12) in this randomized controlled trial publication.
Who Took Part
The study group was 50 patients.
The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.
The primary outcome was the change in serum methylmalonic acid (MMA) levels after one month of treatment.
Blood samples were centralised for analysis and adherence to treatment was verified by an electronic device (MEMS; Aardex Europe, Switzerland).
How the Study Was Run
The design is described as randomized, placebo-controlled, multicenter and parallel-group.
The patients were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Cyanocobalamin (Vitamin B12) group a baseline to be compared against.
Running at several centres spread the Cyanocobalamin (Vitamin B12) study over different clinics and patient groups.
The Cyanocobalamin (Vitamin B12) group and the comparison group ran side by side rather than switching.
The methods mention a period of one month.
Secondary outcomes were changes in total homocysteine and serum vitamin B12 levels.
What Was Measured
Topics PubMed links to this paper include Biomarkers, Blood Specimen Collection, Dietary Supplements, Homocysteine, Least-Squares Analysis, Methylmalonic Acid and Patient Compliance.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and multicenter study of Cyanocobalamin (Vitamin B12) in 50 patients over one month.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (BMC family practice), a journal based in England.
More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.
Our Notes on the Compound
Cyanocobalamin (Vitamin B12): A synthetic form of vitamin B12 (cobalamin), an essential nutrient for DNA synthesis, red blood cell formation and neurological function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.